Comparative Features and Outcomes Between Paediatric T-cell and B-cell Acute Lymphoblastic Leukaemia

Overview

Journal Lancet Oncol

Specialty Oncology

Date 2019 Mar 8

PMID 30842058

Citations 119

Authors

David T Teachey

Ching-Hon Pui

Affiliations

Soon will be listed here.

Abstract

Contemporary paediatric clinical trials have improved 5-year event-free survival above 85% and 5-year overall survival above 90% in B-cell acute lymphoblastic leukaemia (ALL) in many study groups, whilst outcomes for T-cell ALL are still lagging behind by 5-10% in most studies. Several factors have contributed to this discrepant outcome. First, patients with T-cell ALL are generally older than those with B-cell ALL and, therefore, have poorer tolerance to chemotherapy, especially dexamethasone and asparaginase, and have increased risk of extramedullary relapse. Second, a higher proportion of patients with B-cell ALL have favourable genetic subtypes (eg, ETV6-RUNX1 and high hyperdiploidy), which confer a superior outcome compared with favourable subtypes of T-cell ALL. Third, T-cell ALL blasts are generally more resistant to conventional chemotherapeutic drugs than are B-cell ALL blasts. Finally, patients with B-cell ALL are more amendable to available targeted therapies, such as Philadelphia chromosome-positive and some Philadelphia chromosome-like ALL cases to ABL-class tyrosine kinase inhibitors, and CD19-positive and CD22-postive B-cell ALL cases to a variety of immunotherapies. Several novel treatments under investigation might narrow the gap in survival between T-cell ALL and B-cell ALL, although novel treatment options for T-cell ALL are limited.

Citing Articles

Nelarabine in T-cell acute lymphoblastic leukemia: intracellular metabolism and molecular mode-of-action.

Hormann F, Rudd S Leukemia. 2025; 39(3):531-542.

PMID: 39962329 PMC: 11879874. DOI: 10.1038/s41375-025-02529-2.

Imaging Flow Cytometric Identification of Chromosomal Defects in Paediatric Acute Lymphoblastic Leukaemia.

Simpson A, George C, Hui H, Doddi R, Kotecha R, Fuller K Cells. 2025; 14(2).

PMID: 39851542 PMC: 11763943. DOI: 10.3390/cells14020114.

Venetoclax and azacitidine in combination with homoharringtonine, cytarabine, and aclarubicin for salvage therapy of relapsed/refractory T cell acute lymphoblastic leukemia.

Feng L, Li H, Tang A, Xu M, Wang S Int J Hematol. 2025; .

PMID: 39847198 DOI: 10.1007/s12185-025-03915-3.

RSK4 promotes the metastasis of clear cell renal cell carcinoma by activating RUNX1-mediated angiogenesis.

Ma J, Yang Y, Wang K, Liu J, Feng J, Wang G Cancer Biol Ther. 2025; 26(1):2452025.

PMID: 39797421 PMC: 11730630. DOI: 10.1080/15384047.2025.2452025.

Clinical outcomes and safety of CAR-T cells in treatment of T-Cell acute lymphoblastic leukemia/lymphoma.

Ma J, Yan C, Jia X, Zhu H, Yan J, Liu M Ann Hematol. 2024; 104(1):57-63.

PMID: 39692783 DOI: 10.1007/s00277-024-06132-w.

References

Zhang J, McCastlain K, Yoshihara H, Xu B, Chang Y, Churchman M . Deregulation of DUX4 and ERG in acute lymphoblastic leukemia. Nat Genet. 2016; 48(12):1481-1489. PMC: 5144107. DOI: 10.1038/ng.3691. View

Reiter A, Schrappe M, Ludwig W, Hiddemann W, Sauter S, Henze G . Chemotherapy in 998 unselected childhood acute lymphoblastic leukemia patients. Results and conclusions of the multicenter trial ALL-BFM 86. Blood. 1994; 84(9):3122-33. View

Panzer-Grumayer E, Fasching K, Panzer S, Hettinger K, Schmitt K, Stockler-Ipsiroglu S . Nondisjunction of chromosomes leading to hyperdiploid childhood B-cell precursor acute lymphoblastic leukemia is an early event during leukemogenesis. Blood. 2002; 100(1):347-9. DOI: 10.1182/blood-2002-01-0144. View

Pui C, Yang J, Hunger S, Pieters R, Schrappe M, Biondi A . Childhood Acute Lymphoblastic Leukemia: Progress Through Collaboration. J Clin Oncol. 2015; 33(27):2938-48. PMC: 4567699. DOI: 10.1200/JCO.2014.59.1636. View

Hrusak O, de Haas V, Stancikova J, Vakrmanova B, Janotova I, Mejstrikova E . International cooperative study identifies treatment strategy in childhood ambiguous lineage leukemia. Blood. 2018; 132(3):264-276. DOI: 10.1182/blood-2017-12-821363. View

Gu Z, Churchman M, Roberts K, Moore I, Zhou X, Nakitandwe J . PAX5-driven subtypes of B-progenitor acute lymphoblastic leukemia. Nat Genet. 2019; 51(2):296-307. PMC: 6525306. DOI: 10.1038/s41588-018-0315-5. View

Place A, Stevenson K, Vrooman L, Harris M, Hunt S, OBrien J . Intravenous pegylated asparaginase versus intramuscular native Escherichia coli L-asparaginase in newly diagnosed childhood acute lymphoblastic leukaemia (DFCI 05-001): a randomised, open-label phase 3 trial. Lancet Oncol. 2015; 16(16):1677-90. DOI: 10.1016/S1470-2045(15)00363-0. View

Trevino L, Yang W, French D, Hunger S, Carroll W, Devidas M . Germline genomic variants associated with childhood acute lymphoblastic leukemia. Nat Genet. 2009; 41(9):1001-5. PMC: 2762391. DOI: 10.1038/ng.432. View

Pui C, Sandlund J, Pei D, Rivera G, Howard S, Ribeiro R . Results of therapy for acute lymphoblastic leukemia in black and white children. JAMA. 2003; 290(15):2001-7. DOI: 10.1001/jama.290.15.2001. View

10.

Roti G, Stegmaier K . New Approaches to Target T-ALL. Front Oncol. 2014; 4:170. PMC: 4085879. DOI: 10.3389/fonc.2014.00170. View

11.

Igarashi S, Manabe A, Ohara A, Kumagai M, Saito T, Okimoto Y . No advantage of dexamethasone over prednisolone for the outcome of standard- and intermediate-risk childhood acute lymphoblastic leukemia in the Tokyo Children's Cancer Study Group L95-14 protocol. J Clin Oncol. 2005; 23(27):6489-98. DOI: 10.1200/JCO.2005.01.982. View

12.

Hunger S, Lu X, Devidas M, Camitta B, Gaynon P, Winick N . Improved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005: a report from the children's oncology group. J Clin Oncol. 2012; 30(14):1663-9. PMC: 3383113. DOI: 10.1200/JCO.2011.37.8018. View

13.

Lilljebjorn H, Henningsson R, Hyrenius-Wittsten A, Olsson L, Orsmark-Pietras C, von Palffy S . Identification of ETV6-RUNX1-like and DUX4-rearranged subtypes in paediatric B-cell precursor acute lymphoblastic leukaemia. Nat Commun. 2016; 7:11790. PMC: 4897744. DOI: 10.1038/ncomms11790. View

14.

Ward E, DeSantis C, Robbins A, Kohler B, Jemal A . Childhood and adolescent cancer statistics, 2014. CA Cancer J Clin. 2014; 64(2):83-103. DOI: 10.3322/caac.21219. View

15.

Smith M, Arthur D, Camitta B, Carroll A, Crist W, Gaynon P . Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia. J Clin Oncol. 1996; 14(1):18-24. DOI: 10.1200/JCO.1996.14.1.18. View

16.

Bene M, Castoldi G, Knapp W, Ludwig W, Matutes E, Orfao A . Proposals for the immunological classification of acute leukemias. European Group for the Immunological Characterization of Leukemias (EGIL). Leukemia. 1995; 9(10):1783-6. View

17.

Greaves M . A causal mechanism for childhood acute lymphoblastic leukaemia. Nat Rev Cancer. 2018; 18(8):471-484. PMC: 6986894. DOI: 10.1038/s41568-018-0015-6. View

18.

Pui C, Howard S . Current management and challenges of malignant disease in the CNS in paediatric leukaemia. Lancet Oncol. 2008; 9(3):257-68. DOI: 10.1016/S1470-2045(08)70070-6. View

19.

Vora A, Goulden N, Mitchell C, Hancock J, Hough R, Rowntree C . Augmented post-remission therapy for a minimal residual disease-defined high-risk subgroup of children and young people with clinical standard-risk and intermediate-risk acute lymphoblastic leukaemia (UKALL 2003): a randomised controlled trial. Lancet Oncol. 2014; 15(8):809-18. DOI: 10.1016/S1470-2045(14)70243-8. View

20.

Borowitz M, Devidas M, Hunger S, Bowman W, Carroll A, Carroll W . Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study. Blood. 2008; 111(12):5477-85. PMC: 2424148. DOI: 10.1182/blood-2008-01-132837. View